Brief: Relief Therapeutics Holding And Nrx Pharmaceuticals Announce Execution Of Definitive Settlement Agreements

MindMaze Therapeutics Holding SA

14/11/2022 06:24

Nov 14 (Reuters) - Relief Therapeutics Holding Sa
 RLFB.S :
    * AND NRX PHARMACEUTICALS, INC. ANNOUNCE EXECUTION OF
DEFINITIVE
SETTLEMENT AGREEMENTS
    * RELIEF- CO WILL HAVE EXCLUSIVE RIGHT GOING FORWARD AND
OBLIGATION TO USE COMMERCIALLY REASONABLE EFFORTS TO
DEVELOP,COMMERCIALIZE AN AVIPTADIL PRODUCT
    * RELIEF THERAPEUTICS HOLDING - NRX PHARMACEUTICALS WILL
TRANSFER
TO RELIEF ALL OF ASSETS THAT IT PREVIOUSLY USED IN ITS AVIPTADIL
DEVELOPMENT PROGRAM
    * RELIEF-CO AGREED TO USE COMMERCIALLY REASONABLE EFFORTS TO
CONTINUE EXISTING RIGHT TO TRY PROGRAM FOR AVIPTADIL IN UNITED
STATES FOR AT LEAST 2 YEARS
    * RELIEF - CO WILL PAY NRX PHARMACEUTICALS MILESTONE
PAYMENTS IF
IT CAN SUCCESSFULLY OBTAIN COMMERCIAL APPROVAL OF AN AVIPTADIL
PRODUCT
    * NRX PHARMACEUTICALS HAS AGREED NOT TO COMPETE IN
DEVELOPMENT OF
AN AVIPTADIL PRODUCT IN FUTURE
    * RELIEF THERAPEUTICS HOLDING - CO WILL PAY NRX
PHARMACEUTICALS
ROYALTIES BASED ON A PERCENTAGE OF FUTURE SALES OF AN AVIPTADIL
PRODUCT , UP TO A MAXIMUM OF $30 MILLION IN AGGREGATE

Source text for Eikon:  ID:nPnHx7kDa 
Further company coverage:  RLFB.S 
 ((Reuters.Briefs@thomsonreuters.com;))